Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of ...

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of ...

GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models

#Gain Therapeutics Advances GT-02287 with Promising Preclinical Data and Phase 1b Trial Development in Parkinsons Dis...

:' Gain Therapeutics, Inc. (NASDAQ: GANX) has garnered attention at the AD/PD 2025 conference with its recent oral presentation on the promising preclinical data of GT-02287. The data highlights the disease-modifying potential of this investigational therapy in models of GBA1 and idiopathic Parkinson's disease. Additionally, the biopharmaceutical company disclosed the design of its upcoming Phase 1b clinical trial and provided an update on patie…